We propose that through the modulation of MutSα levels, NRIP1 actively participates in the dMMR phenotype of intestinal epithelial cancer cells, and represents a promising prognostic marker to adapt the management of patients with MSI CRC. This evidence concerns the gene NRIP1 and colorectal carcinoma.